Gilead Sciences Inc. (GILD) News

Gilead Sciences Inc. (GILD): $78.12

-0.28 (-0.36%)

POWR Rating

Component Grades








Add GILD to Watchlist
Sign Up

Industry: Biotech




#3 of 382

in industry

Filter GILD News Items

GILD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

GILD News Highlights

  • GILD's 30 day story count now stands at 22.
  • Over the past 19 days, the trend for GILD's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
  • The most mentioned tickers in articles about GILD are CELL, ARC and LUNG.

Latest GILD News From Around the Web

Below are the latest news stories about GILEAD SCIENCES INC that investors may wish to consider to help them evaluate GILD as an investment opportunity.

Kite’s Tecartus® CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory Mantle Cell Lymphoma

SANTA MONICA, Calif., June 06, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announces findings from the largest real-world analysis to date of Tecartus® (brexucabtagene autoleucel) in patients with relapsed or refractory mantle cell lymphoma (R/R MCL), which show that outcomes of Tecartus therapy had consistent high complete response (CR) and overall response rates (ORR), regardless of type of prior treatment, including: Bruton's tyrosine kinase inhibitor (BTKi), bendamustine or autologous

Yahoo | June 6, 2023

Gilead (GILD), Arcus Announce Results From Mid-Stage NSCLC Study

Gilead (GILD) and Arcus announce data from the interim analysis of the mid-stage ARC-7 study on domvanalimab in the NSCLC study.

Yahoo | June 5, 2023

Trodelvy® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer

FOSTER CITY, Calif., June 05, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced longer-term overall survival (OS) results from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) versus comparator chemotherapy (physicians’ choice of chemotherapy, TPC) in patients with HR+/HER2- (IHC0, IHC1+, IHC2+/ISH-) metastatic breast cancer who received endocrine-based therapies and at least two chemotherapies. In this exploratory analysis, Trodelvy demonstrated a clinical

Yahoo | June 5, 2023

Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma

SANTA MONICA, Calif., June 05, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announces detailed results from the overall survival (OS) analysis of the landmark Phase 3 ZUMA-7 study of Yescarta® (axicabtagene ciloleucel [axi-cel]) CAR T-cell therapy compared with historical standard of care (SOC) as initial treatment in the curative setting for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). Yescarta is the first treatment in nearly 30 years to demonstrate a significan

Yahoo | June 5, 2023

Those who invested in Gilead Sciences (NASDAQ:GILD) a year ago are up 28%

Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost...

Yahoo | June 4, 2023

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study

FOSTER CITY, Calif., & HAYWARD, Calif., June 03, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced updated results from an interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations. ARC-7 is the first Phase 2, randomized, open-label study evaluating the comb

Yahoo | June 3, 2023

3 Dividend Stocks You Can Buy Without Any Hesitation

Three Motley Fool contributors identified dividend stocks that should be easy buy decisions for investors. Here's why they think Bristol Myers Squibb (NYSE: BMY), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) are investments you can make in June without any hesitation. David Jagielski (Bristol Myers Squibb):  Bristol Myers Squibb has been paying dividends for more than 90 consecutive years.

Yahoo | June 3, 2023

3 Undervalued Biotech Stocks to Buy Before They Blast Off

Fundamental analysis makes these three undervalued biotech stocks to buy plus they have other catalysts that make them compelling.

Chris Markoch on InvestorPlace | June 2, 2023

15 Best Healthcare Stocks To Buy Now

In this article, we will take a look at the 15 best healthcare stocks to buy now. For more stocks, head on over to 5 Best Healthcare Stocks To Buy Now. In the midst of uncertain economic conditions globally, the healthcare sector has displayed a notable degree of resilience. Historically, the demand for healthcare products […]

Yahoo | June 1, 2023

Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA

FOSTER CITY, Calif. & SANTA MONICA, Calif., June 01, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 17 abstracts from its industry-leading cell therapy portfolio and growing blood cancer pipeline at the upcoming 2023 European Hematology Association (EHA) Annual Congress being held in Frankfurt, Germany, June 8-11, and virtually June 14-15.

Yahoo | June 1, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7461 seconds.